Embecta Corporation (EMBC – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Travis ...

In a report released yesterday, Kallum Titchmarsh from Morgan Stanley maintained a Sell rating on Embecta Corporation (EMBC – Research Report), ...

Q4 2024 Earnings Call Transcript November 26, 2024 Embecta Corp. misses on earnings expectations. Reported EPS is $ EPS, ...

Embecta (EMBC) stock gains as BTIG upgrades the stock citing an end to its patch pump program announced with its Q4 FY24 results. Read more here.

Despite winning an FDA green light nearly three months ago for its first wearable insulin delivery system, Embecta is now ...

Embecta Corp (EMBC) reports a 4.1% revenue increase while navigating restructuring and future growth opportunities.

Kurdikar, CEO of Embecta (EMBC) said, “As our stand-up work nears completion and following an in-depth review of our ...

Embecta reports fourth quarter earnings beating estimates, discontinues insulin patch program, and announces restructuring ...

Embecta announced today that it discontinued its insulin patch pump program and plans to initiate a restructuring plan.

Good day, and welcome to the Embecta fourth quarter of fiscal year 2024 earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like ...

The Board of Directors of Embecta Corp. ("embecta”) (Nasdaq: EMBC) has declared a quarterly cash dividend of $0.15 for each ...

Embecta also said it expects to earn between $2.70 and $2.90 a share on an adjusted basis for all of 2025, easily surpassing the average analyst estimate of $2.27 per share. Revenue is anticipated at ...